1Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure[J]. JAMA, 1996,275 (20): 1557-1662.
2DiBona GF, Kopp UC. Neural control of renal function [J]. Physiol Rev, 1997,77 ( 1 ) : 75-197.
3Asai K, Yang GP, Geng YJ, et al. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse[J]. J Clin Invest, 1999,104 (5) : 551-558.
4Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage I J]. Hypertension, 1999,34 (4 Pt 2):724- 728.
5Grassi G, Arenare F, Pieruzzi F, et al. Sympathetic activation in cardiovascular and renal disease[Jl. J Nephrol, 2009,22 (2) : 190-195.
6Smith PA, Graham LN, Mackintosh AF, et al. Relationship between central sympathetic activity and stages of human hypertension[J]. Am J Hypertens, 2004,17(3) :217-222.
7Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A muhicentre safety and proof-of-principle cohort study [J]. Lancet, 2009,373(9671 ) : 1275-1281.
8Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial [J]. Lancet, 2010,376(9756) : 1903-1909.
9Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients[J]. Am J Hypertens, 2008,21 (5) : 500-508.
10Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension : A meta-analysis [ J 1. Am J Hypertens, 2010,23 (8) :876-881.
